Sorting Out Nonadherence and Airway Inflammation in Treatment Escalation for Severe Asthma

In their study in this issue of the Journal, Heaney and colleagues (pp. 454-464) assert that profiling of fractional exhaled nitric oxide (FENO), blood eosinophil response, and adherence to inhaled corticosteroid/long-acting ß-agonist (ICS/LABA) therapy can identify those requiring biologic treatmen...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 199; no. 4; pp. 400 - 402
Main Author Bender, Bruce G
Format Journal Article
LanguageEnglish
Published United States American Thoracic Society 15.02.2019
Subjects
Anti-Asthmatic Agents
Asthma
Biomarkers
Humans
Inflammation
Nitric Oxide
Patients
Questionnaires
Respiratory System
School dropouts
United Kingdom > UK
United States > US
Colorado
Online AccessGet full text

Cover

More Information
Summary:In their study in this issue of the Journal, Heaney and colleagues (pp. 454-464) assert that profiling of fractional exhaled nitric oxide (FENO), blood eosinophil response, and adherence to inhaled corticosteroid/long-acting ß-agonist (ICS/LABA) therapy can identify those requiring biologic treatment (4). To evaluate adherence, the investigators used a novel and clever acoustic monitoring technology that time stamps a sound file, which can then be analyzed to determine adherence with inhaled medication (Inhaler Compliance Assessment [5]). Heaney and colleagues introduce the possibility of developing a clinically helpful, standardized protocol for evaluating adherence and inflammation control that can differentiate those patients who should be placed on a biologic medication from those whose inadequate symptom control may be a result of nonadherence rather than ICS/LABA failure (4).
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201811-2144ed